March 1990
Volume 31, Issue 3
Free
Articles  |   March 1990
Cefazolin levels after intravitreal injection. Effects of inflammation and surgery.
Author Affiliations
  • L Ficker
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia 30322.
  • T A Meredith
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia 30322.
  • S Gardner
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia 30322.
  • L A Wilson
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia 30322.
Investigative Ophthalmology & Visual Science March 1990, Vol.31, 502-505. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L Ficker, T A Meredith, S Gardner, L A Wilson; Cefazolin levels after intravitreal injection. Effects of inflammation and surgery.. Invest. Ophthalmol. Vis. Sci. 1990;31(3):502-505.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

Cefazolin (2.25 mg) was injected into the vitreous cavity of phakic, aphakic, and aphakic/vitrectomized rabbits; inflamed eyes were compared to controls. Vitreous levels of cefazolin were determined at selected times from 2 to 48 hr, and the half-life was calculated. The effect of inflammation was to increase the half-life or to reduce the rate of elimination of cefazolin from the vitreous cavity. The drug was cleared substantially faster from aphakic/vitrectomized eyes than from phakic or aphakic eyes. Vitreous levels of cefazolin were above the MIC for most common gram-positive organisms causing endophthalmitis in all study groups at 24 hr, but in only the phakic inflamed eyes and in the aphakic eyes with intact vitreous at 48 hr.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×